DAFNA Capital Management LLC bought a new stake in shares of Arcus Biosciences Inc (NYSE:RCUS) during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 7,500 shares of the company’s stock, valued at approximately $116,000.

A number of other large investors also recently made changes to their positions in RCUS. Foresite Capital Management III LLC acquired a new stake in Arcus Biosciences during the 1st quarter valued at $42,080,000. BVF Inc. IL acquired a new stake in Arcus Biosciences during the 1st quarter valued at $19,606,000. Foresite Capital Management IV LLC acquired a new stake in Arcus Biosciences during the 1st quarter valued at $10,036,000. Board of Trustees of The Leland Stanford Junior University acquired a new stake in Arcus Biosciences during the 1st quarter valued at $9,651,000. Finally, Lord Abbett & CO. LLC acquired a new stake in Arcus Biosciences during the 1st quarter valued at $4,643,000. Hedge funds and other institutional investors own 33.24% of the company’s stock.

Shares of Arcus Biosciences stock opened at $16.41 on Wednesday. Arcus Biosciences Inc has a fifty-two week low of $13.26 and a fifty-two week high of $22.10.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings results on Wednesday, May 9th. The company reported ($1.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.49). The business had revenue of $1.25 million during the quarter, compared to the consensus estimate of $1.30 million. analysts anticipate that Arcus Biosciences Inc will post -1.82 earnings per share for the current year.

RCUS has been the topic of a number of recent analyst reports. Goldman Sachs Group initiated coverage on Arcus Biosciences in a research note on Monday, April 9th. They set a “neutral” rating and a $18.00 price target on the stock. Leerink Swann initiated coverage on Arcus Biosciences in a research note on Monday, April 9th. They set an “outperform” rating and a $21.00 price target on the stock. Finally, Citigroup initiated coverage on Arcus Biosciences in a research note on Monday, April 9th. They set a “buy” rating and a $18.00 price target on the stock.

In other news, CEO Terry J. Rosen bought 66,666 shares of the business’s stock in a transaction that occurred on Monday, March 19th. The shares were acquired at an average cost of $15.00 per share, with a total value of $999,990.00. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Kathryn E. Falberg bought 30,000 shares of the business’s stock in a transaction that occurred on Monday, March 19th. The stock was purchased at an average cost of $15.00 per share, for a total transaction of $450,000.00. The disclosure for this purchase can be found here.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. It is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody.

Want to see what other hedge funds are holding RCUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arcus Biosciences Inc (NYSE:RCUS).

Institutional Ownership by Quarter for Arcus Biosciences (NYSE:RCUS)

Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.